| Literature DB >> 34831708 |
Beata Hornik1, Jan Duława2,3, Jacek Durmała4.
Abstract
Metabolic syndrome (MS) and anxiety disorders are common problems among hemodialysis patients (HD). However, there have been no studies defining the role of physical activity in reducing anxiety in HD patients with MS. This study was aimed to determine the effects on the severity of anxiety of a four-week rehabilitation program for HD patients, with or without metabolic syndrome (MS), planned and adapted to their abilities. The study was single-center, interventional, non-randomized, and prospective. Fifty-eight individuals completed the project (28 HD patients and 30 controls (C) with normal kidney function). Each group was divided into two subgroups with respect to MS. The mean age of the subjects in the HD and C groups was 56.9 ± 13.3 years (x¯ ± SD) and 61.5 ± 8.3 years (x¯ ± SD), respectively. Planned and adapted to the patient's abilities, the rehabilitation program based on physiotherapy was provided to each subject for 4 weeks. Baseline and post-intervention determined anxiety levels using the State-Trait Anxiety Inventory (STAI). The X1 scale tests state anxiety, and the X2 scale tests trait anxiety. Post-intervention, there was no significant difference in the intensity of state anxiety observed in HD patients compared to C with normal renal function, as observed before the program. After four weeks of regular physical activity planned and adapted to the patient's abilities in an inpatient ward, the level of state anxiety (X1) and trait anxiety (X2) lowered considerably in all HD patients (respectively: 35.1 ± 8.0 vs. 29.2 ± 5.0, p = 0.001 for X1 and 41.8 ± 9.1 vs. 38.1 ± 5.9, p = 0.008 for X2). The rehabilitation program significantly reduced the intensity of state anxiety (X1) in HD patients with MS (35.8 ± 7.9 vs. 29.2 ± 5.1; p = 0.01). The rehabilitation program helped to significantly reduce the intensity of trait anxiety (X2) in HD patients without MS (41.9 ± 10.7 vs. 36.9 ± 5.9; p = 0.04). Four-week physical activity planned and adapted to the patient's abilities reduces the intensity of anxiety in HD patients and controls with normal renal function. HD patients with MS benefit more in terms of reducing perceived state anxiety, and HD patients without MS in terms of reducing trait anxiety.Entities:
Keywords: anxiety; hemodialysis; metabolic syndrome; physical activity; rehabilitation
Mesh:
Year: 2021 PMID: 34831708 PMCID: PMC8622865 DOI: 10.3390/ijerph182211952
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Baseline characteristics of patients participating in the study (n = 58).
| Variables | Study Group (HD) | Control Group (C) | |
|---|---|---|---|
| Age (years) | 56.9 ± 13.3 | 61.5 ± 8.3 | 0.12 |
| Sex, | 16 (57)/12 (43) | 15 (50)/15 (50) | 0.61 |
| Dialysis vintage (months) | 50.6 ± 73.4 (range = 5–272) | - | |
| Frequency of dialysis, | - | ||
| 3 times per week | 24 (85.7) | ||
| 4 times per week | 3 (10.7) | ||
| 5 times per week | 1 (3.6) | ||
| Dialysis adequacy ( | 1.41 ± 0.23 | - | |
| BMI (kg/m2) | 27.1 ± 6.08 | 29.2 ± 5.3 | 0.16 |
| Weight (kg) | 74.1 ± 20.1 | 79.9 ± 17.7 | 0.25 |
| Vascular access, n (%) | - | ||
| arteriovenous fistulas | 24 (85.6) | ||
| arteriovenous grafts | 2 (7.2) | ||
| central venous catheters | 2 (7.2) | ||
| Cause of end-stage kidney disease, | - | ||
| glomerulonephritis | 7 (25.1) | ||
| diabetic kidney disease | 6 (21.4) | ||
| hypertension nephropathy | 6 (21.4) | ||
| other | 9 (32.1) | ||
| CCI (point) | 4.5 ± 3.6 | 1.03 ± 0.61 | 0.001 |
| Metabolic syndrome, | 14 (50) | 13 (43.3) | 0.79 |
| Diabetes, | 7 (25) | 4(14.3) | 0.32 |
| Waist circumference (cm) | 96.3 ± 17.0 | 96.7 ± 13.4 | 0.92 |
| Estimated GFR (mL/min/1.73 m2) | 9.3 ± 3.6 | 97.6 ± 28.1 | <0.001 |
| Hemoglobin (g/dL) | 11.16 ± 1.34 | 13.85 ± 0.81 | <0.001 |
| Uric acid (mg/dL) | 5.24 ± 1.44 | 5.96 ± 1.58 | 0.08 |
| Creatinine (mg/dL) | 6.750 ± 2.435 | 0.843 ± 0.156 | <0.001 |
| Phosphorus (mg/dL) | 5.234 ± 1.264 | 1.277 ± 0.209 | <0.001 |
| Sodium (mmol/dL) | 139.6 ± 2.9 | 139.4 ± 2.0 | 0.70 |
| Potassium (mmol/dL) | 5.230 ± 0.522 | 4.743 ± 0.431 | <0.001 |
| PTH (pg/mL) | 210.1 ± 187.8 | 55.41 ± 25.39 | <0.001 |
| X1 | 35.1 ± 8.0 | 30.3 ± 7.0 | 0.01 |
| X2 | 41.8 ± 9.1 | 39.9 ± 9.4 | 0.53 |
Note: Results are the mean ± standard deviation (SD) or numbers (and percentages); significant at p-value <0.05. Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; GFR, glomerular filtration rate; PTH, parathyroid hormone; X1, state anxiety; X2, trait anxiety.
Baseline comparison of the level of anxiety in the study (HD) and control group (C) with metabolic syndrome (MS) and without metabolic syndrome (nMS).
| Study Group | Control Group | |||||
|---|---|---|---|---|---|---|
| HD-MS | HD-nMS | C-MS | C-nMS | HD-MS | HD-nMS | |
| X1 ( | 35.8 ± 7.9 | 34.5 ± 8.2 | 29.1 ± 6.6 | 31.2 ± 7.3 | 0.03 | 0.26 |
| X2 ( | 41.7 ± 7.5 | 41.9 ± 10.7 | 39.7 ± 9,4 | 40.1 ± 9.7 | 0.66 | 0.84 |
Note: Results are the mean ± SD; significant at p-value < 0.05. Abbreviations: X1, state anxiety; X2, trait anxiety; HD, hemodialysis patients; C, patients with normal renal function; HD-MS, hemodialysis patients with metabolic syndrome; HD-nMS, hemodialysis patients without metabolic syndrome; C-MS, patients with normal renal function with metabolic syndrome; C-nMS, patients with normal renal function without metabolic syndrome.
Effect of rehabilitation program on the studied parameters in study (HD) and control group (C).
| Study Group | Control Group | |||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| X1 ( | 35.1 ± 8.0 | 29.2 ± 5.0 | 30.3 ± 7.0 | 27.8 ± 6.7 | 0.01 | 0.21 |
| X2 ( | 41.8 ± 9.1 | 38.1 ± 5.9 | 39.9 ± 9.4 | 36.8 ± 7.2 | 0.53 | 0.65 |
Note: Results are the mean ± SD; significant at p-value < 0.05. Abbreviations: X1, state anxiety; X2, trait anxiety; HD, hemodialysis patients; C, patients with normal renal function.
Effect of rehabilitation program on the studied parameters in the study (HD) and control group (C) with metabolic syndrome (MS).
| Study Group | Control Group | |||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| X1 ( | 35.8 ± 7.9 | 29.2 ± 5.1 | 29.1 ± 6.6 | 24.8 ± 3.5 | 0.03 | 0.04 |
| X2 ( | 41.7 ± 7.5 | 39.3 ± 5.8 | 39.7 ± 9.4 | 35.6 ± 6.5 | 0.66 | 0.21 |
Note: Results are the mean ± SD; significant at p-value < 0.05. Abbreviations: X1, state anxiety; X2, trait anxiety; HD-MS, hemodialysis patients with metabolic syndrome; C-MS, patients with normal renal function with metabolic syndrome.
Effect of rehabilitation program on the studied parameters in the study (HD) and control group (C) without metabolic syndrome (nMS).
| Study Group | Control Group | |||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| X1 ( | 34.5 ± 8.2 | 29.1 ± 5.1 | 31.2 ± 7.3 | 30.1 ± 7.7 | 0.26 | 0.95 |
| X2 ( | 41.9 ± 10.7 | 36.9 ± 5.9 | 40.1 ± 9.7 | 37.7 ± 7.8 | 0.84 | 0.56 |
Note: Results are the mean ± SD; significant at p-value < 0.05. Abbreviations: X1, state anxiety; X2, trait anxiety; HD-nMS, hemodialysis patients without metabolic syndrome; C-nMS, patients with normal renal function without metabolic syndrome.